Affordable Access

Access to the full text

Histone Deacetylases as Epigenetic Targets for Treating Parkinson’s Disease

Authors
  • li;, he yan
Publication Date
May 21, 2022
Identifiers
DOI: 10.3390/brainsci12050672
OAI: oai:mdpi.com:/2076-3425/12/5/672/
Source
MDPI
Keywords
Language
English
License
Green
External links

Abstract

Parkinson’s disease (PD) is a chronic progressive neurodegenerative disease that is increasingly becoming a global threat to the health and life of the elderly worldwide. Although there are some drugs clinically available for treating PD, these treatments can only alleviate the symptoms of PD patients but cannot completely cure the disease. Therefore, exploring other potential mechanisms to develop more effective treatments that can modify the course of PD is still highly desirable. Over the last two decades, histone deacetylases, as an important group of epigenetic targets, have attracted much attention in drug discovery. This review focused on the current knowledge about histone deacetylases involved in PD pathophysiology and their inhibitors used in PD studies. Further perspectives related to small molecules that can inhibit or degrade histone deacetylases to treat PD were also discussed.

Report this publication

Statistics

Seen <100 times